Clinical and immunological efficiency of anaferon (pediatric formulation) in calicivirus infection in children.
Therapy with anaferon (pediatric formulation) during the acute period of calicivirus infection shortened the duration of the main symptoms of the disease and period of virus release. Changes in the immunological status included increased production of IgA and IgM and activation of IFN-alpha synthesis.
Tikhomirova
O V
OV
Institute of Children Infections, Federal Agency for Health Care and Social Development, St. Petersburg.
Razd'yakonova
I V
IV
Bekhtereva
M K
MK
Zheleznikova
G F
GF
Monakhova
N E
NE
Sirotkin
A K
AK
D000208:Acute Disease; D000293:Adolescent; D000906:Antibodies / Q000494:pharmacology* / Q000627:therapeutic use*; D000998:Antiviral Agents / Q000494:pharmacology / Q000627:therapeutic use; D017250:Caliciviridae Infections / Q000188:drug therapy* / Q000378:metabolism / Q000821:virology; D002648:Child; D002675:Child, Preschool; D004797:Enzyme-Linked Immunosorbent Assay; D005260:Female; D006801:Humans; D007107:Immune System / Q000187:drug effects*; D007070:Immunoglobulin A / Q000378:metabolism; D007075:Immunoglobulin M / Q000378:metabolism; D016130:Immunophenotyping; D007223:Infant; D007369:Interferon Inducers / Q000627:therapeutic use*; D016898:Interferon-alpha / Q000378:metabolism; D007410:Intestinal Diseases / Q000188:drug therapy* / Q000378:metabolism / Q000821:virology*; D008297:Male; D016896:Treatment Outcome
D000906:Antibodies; D000998:Antiviral Agents; D007070:Immunoglobulin A; D007075:Immunoglobulin M; D007369:Interferon Inducers; D016898:Interferon-alpha; C547732:anaferon